Clinical and Translational Science - Principles of Human Research

Clinical and Translational Science - Principles of Human Research

von: David Robertson, Gordon H. Williams (Eds.)

Elsevier Trade Monographs, 2008

ISBN: 9780080920191 , 600 Seiten

Format: PDF

Kopierschutz: DRM

Windows PC,Mac OSX Apple iPad, Android Tablet PC's

Preis: 103,00 EUR

Mehr zum Inhalt

Clinical and Translational Science - Principles of Human Research


 

Front Cover

1

Clinical and Translational Science

4

Copyright Page

5

Contents

8

List of contributors

10

Foreword

14

Acknowledgments

16

Introduction to Clinical Research

18

HISTORICAL BACKGROUND

18

ORGANIZATION OF THIS BOOK

20

REFERENCES

21

Part I: Fundamental Principles

22

Chapter 1 Patient-Oriented Research: Clinical Pathophysiology and Clinical Therapeutics

24

INTRODUCTION

24

TYPES OF PATIENT-ORIENTED RESEARCH

24

THE ROLE OF PATIENT-ORIENTED RESEARCH IN TRANSLATIONAL RESEARCH

27

SEQUENCE OF INVESTIGATION

27

CONCLUSIONS

31

REFERENCES

32

Chapter 2 Clinical Trials

34

INTRODUCTION

34

HISTORY

34

PHASES OF EVALUATION OF THERAPIES

34

CRITICAL GENERAL CONCEPTS

35

EXPRESSING CLINICAL TRIAL RESULTS

36

CONCEPTS UNDERLYING TRIAL DESIGN

38

GENERAL DESIGN CONSIDERATIONS

41

LEGAL AND ETHICAL ISSUES

43

HYPOTHESIS FORMULATION

47

PUBLICATION BIAS

48

STATISTICAL CONSIDERATIONS

48

META-ANALYSIS AND SYSTEMATIC OVERVIEWS

49

UNDERSTANDING COVARIATES AND SUBGROUPS

50

THERAPEUTIC TRUISMS

51

STUDY ORGANIZATION

51

INTEGRATION INTO PRACTICE

54

THE FUTURE

55

ACKNOWLEDGMENT

55

REFERENCES

56

Part II: Approaches

60

Chapter 3 Experimental Design

62

INTRODUCTION

62

HYPOTHESIS DEVELOPMENT

62

STUDY DESIGN OPTIONS

63

CONTROL OF BIAS

64

SAMPLE SIZE

66

ENDPOINTS

68

DATA MANAGEMENT

71

STATISTICAL ANALYSIS

75

CONCLUSION

77

REFERENCES

77

Chapter 4 Introduction to Biostatistics Ideas

80

BIOSTATISTICS: WHAT IS IT?

80

EVIDENCE: HOW MANY HEADS ON THIS COIN?

80

POPULATIONS AND DISTRIBUTIONS

81

SAMPLES

81

CLINICAL MEASURES OF INTEREST: WHAT DO WE WANT TO KNOW?

81

DATA AS SAMPLES: DISPLAY, LOOK AND THINK

83

THE MOST IMPORTANT PROBABILITY MODEL IN MEDICINE

83

THE CIRCLE OF INFERENCE

85

CENTRAL LIMIT THEOREM (CLT)

85

ESTIMATING THE TRUE POPULATION VALUE

86

TESTING PRE-SPECIFIED HYPOTHESES

87

THE MIGHTY P

87

REGRESSION ANALYSIS

88

THE MAIN POINTS ONCE AGAIN

88

REFERENCES

89

Chapter 5 Measurement of Biological Materials

90

INTRODUCTION

90

IMMUNOASSAYS AND IMMUNOCHEMISTRY

90

RADIOIMMUNOASSAYS

91

CHROMATOGRAPHY

93

MASS SPECTROMETRY (MS)

96

GENOMICS (GENE EXPRESSION MICROARRAYS)

99

PROTEOMICS

101

METABOLOMICS

103

REFERENCES

106

Chapter 6 Imaging Tools in Human Research

108

INTRODUCTION

108

IMAGING TECHNOLOGIES: A BRIEF OVERVIEW

108

IMAGING TECHNOLOGIES: HUMANS AND SMALL ANIMALS

111

SUMMARY

123

ACKNOWLEDGMENTS

123

REFERENCE

123

Chapter 7 Imaging Tools in Cardiovascular Research

126

INTRODUCTION

126

IMAGING AND RISK STRATIFICATION

126

PRESSURE WAVEFORM ANALYSIS AND ARTERIAL STIFFNESS

129

ARTERIAL IMAGING

135

ULTRASOUND IMAGING OF THE HEART

138

SUMMARY

139

REFERENCES

141

Chapter 8 Nanotechnology in Clinical and Translational Research

144

INTRODUCTION AND HISTORICAL PERSPECTIVE

144

NANOTECHNOLOGY IN BASIC RESEARCH APPLICATIONS SUPPORTING CLINICAL TRANSLATION

145

CLINICAL APPLICATIONS OF NANOTECHNOLOGY FOR RESEARCH

145

CONCLUSION AND FUTURE DIRECTIONS IN NANOMEDICINE

154

REFERENCES

154

Chapter 9 The Use of Questionnaires and Surveys

158

INTRODUCTION

158

THE PRACTICE OF QUESTIONNAIRE AND SURVEY MEASUREMENT

158

REFERENCES

173

Chapter 10 Information Technology

176

INTRODUCTION

176

CLINICAL DATA REPOSITORIES (CDRs)

176

PRINCIPLES OF DATA WAREHOUSING

177

INFORMATION TECHNOLOGY SUPPORT OF PARTICIPANT RECRUITMENT

182

PRINCIPLES OF DATA COLLECTION

183

DATA STANDARDS

184

CLINICAL TRIAL MANAGEMENT SYSTEMS

185

PUBLICLY AVAILABLE DATABASES

186

THE GROWING IMPACT OF THE WEB

187

SUMMARY

187

REFERENCES

187

Part III: Infrastructure

190

Chapter 11 Clinical and Translational Science Infrastructure

192

INTRODUCTION

192

BACKGROUND

192

REINVENTING THE CLINICAL RESEARCH INFRASTRUCTURE

193

CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTES

194

STRUCTURAL COMPONENTS OF A CLINICAL AND TRANSLATIONAL SCIENCE AWARD

195

CTSA SCIENTIFIC REVIEW

198

COLLECTIVE INITIATIVES OF THE CTSA CONSORTIUM

200

CONCLUSION

201

REFERENCES

202

Chapter 12 Industry-Sponsored Clinical Research in Academia

204

INTRODUCTION

204

THE PUBLIC PERSPECTIVE

204

THE AHC PERSPECTIVE

205

THE INDUSTRY PERSPECTIVE

205

THE INVESTIGATORS’ PERSPECTIVE

206

MATCHING INDUSTRY NEEDS AND AHC INTERESTS

206

ACADEMIC CLINICAL TRIALS CENTERS AS A SOLUTION

207

FINANCING CTCs

207

IT SOLUTIONS TO IMPROVE PATIENT ENROLLMENT

208

CONCLUDING REMARKS

208

ACKNOWLEDGMENT

209

REFERENCES

209

Part IV: Education, Training and Career Choices

210

Chapter 13 Training Basic, Clinical and Translational Investigators

212

INTRODUCTION

212

OVERVIEW

212

DIDACTIC CURRICULUM

213

DEGREE-GRANTING PROGRAMS IN CLINICAL OR TRANSLATIONAL RESEARCH

218

THE MENTORED RESEARCH EXPERIENCE

219

CAREER DEVELOPMENT RESOURCES

219

FUNDING FOR TRAINING CLINICAL AND TRANSLATIONAL INVESTIGATORS

219

REFERENCES

220

Chapter 14 A Stepwise Approach to a Career in Translational Research

222

DEFINITIONAL ISSUES

222

HISTORICAL PERSPECTIVE

222

STEP 1: THE STARTING POINT

223

STEP 2: THE NEED FOR NORMATIVE DATA AND CONTROL POPULATIONS

224

STEP 3: ENGAGEMENT OF RELEVANT BASIC RESEARCHERS AND TECHNOLOGIES

224

STEP 4: IDENTIFYING TRACTABLE PROBLEMS

224

STEP 5: IDENTIFYING APPROPRIATE MENTORS ACROSS A CAREER

225

STEP 6: OBTAINING SUCCESSFUL INDEPENDENT FUNDING

225

STEP 7: THE PERILS OF SENIOR LEADERSHIP

226

SUMMARY

226

REFERENCES

226

Chapter 15 Physician Careers in Industry

228

INTRODUCTION

228

PHASE 1 STUDIES

228

PHASE 2 STUDIES

229

PHASE 3 STUDIES

229

PHASE 4 STUDIES

229

CAREERS IN THE PHARMACEUTICAL INDUSTRY

229

CONCLUSION

236

REFERENCES

236

Part V: Funding

238

Chapter 16 Governmental Support of Research

240

OVERVIEW

240

INTRODUCTION

240

UNITED STATES GOVERNMENT SCIENTIFIC PROGRAMS IN 2007

240

SCIENTIFIC PROGRAMS IN EUROPE, CANADA AND AUSTRALIA/NEW ZEALAND

247

SCIENTIFIC PROGRAMS IN ASIA, AFRICA AND SOUTH/CENTRAL AMERICA AND THE CARIBBEAN

249

CURRENT SUPPORT FOR CLINICAL AND TRANSLATIONAL RESEARCH

253

PUTTING GOVERNMENT HEALTH RESEARCH INTO PERSPECTIVE

254

ACKNOWLEDGMENT

254

BIBLIOGRAPHY

255

REFERENCES

256

Chapter 17 Support of Health Research by Private Philanthropy

258

OVERVIEW

258

INTRODUCTION: GROWTH IN AMERICAN PHILANTHROPY AND ITS ROLE IN SUPPORTING MEDICAL RESEARCH

258

TYPES OF NONPROFIT, NONGOVERNMENTAL FUNDING FOR MEDICAL RESEARCH

260

FUNDING ALONG THE CONTINUUM OF BIOMEDICAL AND HEALTH RESEARCH

264

FOUNDATION FUNDING STRATEGIES – ‘HOW’ TO FUND

270

APPROACHING FOUNDATIONS

271

SUMMARY

273

ACKNOWLEDGMENTS

274

REFERENCES

274

Chapter 18 Pharmaceutical and Biotechnology Sector Support of Research

276

INTRODUCTION

276

THE DRUG DEVELOPMENT PROCESS

276

BASIC SCIENCE WITHIN THE PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS

277

DEVELOPMENTAL RESEARCH – A CONTRAST TO ACADEMIA AND GOVERNMENT

278

CLINICAL RESEARCH AND DEVELOPMENT

279

MARKETED PRODUCT RESEARCH

281

SUMMARY

281

FURTHER READING

282

Part VI: Human Genetics

284

Chapter 19 Introduction to Human Genetics

286

INTRODUCTION

286

BASIC MOLECULAR GENETICS

286

DNA STRUCTURE

286

DNA REPLICATION

287

TRANSCRIPTION

287

TRANSLATION

288

CHROMOSOME STRUCTURE AND FUNCTION

289

MITOSIS AND MEIOSIS

290

PATTERNS OF GENETIC TRANSMISSION

291

SINGLE GENE INHERITANCE (MENDELIAN INHERITANCE)

291

NONMEDELIAN INHERITANCE

292

MULTIFACTORIAL INHERITANCE (POLYGENIC INHERITANCE)

295

CYTOGENETICS AND CHROMOSOMAL DISORDERS

296

THE HUMAN GENOME

297

STRUCTURE AND ORGANIZATION OF THE GENOME

297

GENETIC VARIATION

298

MEDICAL APPLICATIONS

301

MOLECULAR DIAGNOSTIC TESTING

301

THERAPY OF GENETIC DISEASE

302

GENETIC COUNSELING

305

PHENOTYPING AND CLINICAL RESEARCH

307

THE PHENOTYPIC CHALLENGE

307

GENOTYPE–ENVIRONMENT INTERACTION

307

PHENOTYPIC COMPLEXITY

307

REFERENCES

308

BIBLOGRAPHY

308

Chapter 20 Epidemiologic and Population Genetic Studies

310

INTRODUCTION

310

DESIGN ISSUES IN GENETIC ASSOCIATION STUDIES

310

INTERPRETING RESULTS OF GENETIC ASSOCIATION STUDIES

314

FUTURE DIRECTIONS

318

REFERENCES

319

Chapter 21 Pharmacogenetics of Drug Metabolism

322

INTRODUCTION

322

PHARMACOGENETICS OF DRUG METABOLISM: HISTORICAL ASPECTS

323

GENETIC POLYMORPHISMS OF INDIVIDUAL DRUG METABOLIZING GENES

324

UGT

335

CONCLUSIONS

337

REFERENCES

337

Part VII: Human Pharmacology

340

Chapter 22 Introduction to Clinical Pharmacology

342

OVERVIEW

342

INTRODUCTION: MECHANISMS OF DRUG DISPOSITION AND INTERACTIONS

342

PRINCIPLES OF PHARMACOKINETICS

349

CONCLUSION

356

REFERENCES

356

Chapter 23 Toxicology and Genetics of Adverse Drug Events

360

THE MULTIFACTORIAL NATURE OF ADVERSE DRUG EVENTS

360

TYPES OF ADVERSE DRUG EVENTS

361

GENETICS TO GENOMICS

364

REFERENCES

364

Chapter 24 Good Clinical Practice and Good Laboratory Practice

366

OVERVIEW

366

GOOD CLINICAL PRACTICE

366

DEFINITION

366

RULES AND REGULATIONS

368

CLINICAL PRACTICE AND RESEARCH

369

KEY PARTICIPANTS IN CLINICAL RESEARCH

370

DOCUMENTATION AND RECORD KEEPING

374

DATA MANAGEMENT AND PRESENTATION

375

MONITORING AND COMPLIANCE

375

CONCLUSION

376

GOOD LABORATORY PRACTICE

376

DEFINITION AND SCOPE

376

ORGANIZATION AND PERSONNEL

377

MANAGEMENT OF THE TESTING FACILITY

377

TEST, REFERENCE AND CONTROL ARTICLES

378

PROTOCOL FOR AND CONDUCT OF A NONCLINICAL LABORATORY STUDY

379

RECORD KEEPING

379

REPORTING OF NONCLINICAL LABORATORY STUDY RESULTS

379

DISQUALIFICATION OF LABORATORY FACILITY RESOURCES

379

CONCLUSION

380

REFERENCES

380

Chapter 25 Modern Drug Discovery and Development

382

BACKGROUND: THE IRONY OF INNOVATION

382

DRUG DISCOVERY THROUGH THE TWENTIETH CENTURY

382

DRUG DISCOVERY IN THE TWENTY-FIRST CENTURY

384

PRECLINICAL DEVELOPMENT

387

CLINICAL DEVELOPMENT

389

NEW DRUG DEVELOPMENT PARADIGMS

396

REFERENCES

398

Part VIII: Societal Context of Human Research

402

Chapter 26 Translating Science to the Bedside: The Innovation Pipeline

404

REALITIES OF THE MARKETPLACE

404

IDEAS AND INNOVATIONS

407

WORKING WITH INDUSTRY

409

ENTREPRENEURSHIP

412

CLINICAL EVALUATION OF INNOVATIVE PRODUCTS

414

CONFLICTS OF INTEREST

417

SUMMARY

419

NOTES

419

BIBLIOGRAPHY

420

Chapter 27 Regulatory Environment

422

INTRODUCTION

422

THE US FOOD AND DRUG ADMINISTRATION

422

THE INVESTIGATIONAL NEW DRUG (IND) APPLICATION

425

OTHER REGULATORY AGENCIES

434

CONCLUSIONS

434

ACKNOWLEDGMENTS

435

BIBLIOGRAPHY

435

REFERENCES

435

Chapter 28 Ethical Issues in Translational Research and Clinical Investigation

436

INTRODUCTION

436

RESPONSIBILITY IN SCIENCE AND SOCIETY

437

ETHICS AND TRANSLATIONAL RESEARCH

437

GUIDING PRINCIPLES FOR THE RESPONSIBLE TRANSLATIONAL INVESTIGATOR

439

BEYOND ETHICS: REGULATIONS, COMPLIANCE AND PROFESSIONALISM IN TRANSLATIONAL RESEARCH

440

JUSTICE, BENEFICENCE AND RESPECT FOR PERSONS: FROM PRINCIPLES TO PRACTICE

441

REGULATION OF RESEARCH AND PROTECTION OF SUBJECTS

442

INDIVIDUALS AND THE CLINICAL RESEARCH PROCESS

447

PROFESSIONALISM IN CLINICAL RESEARCH

448

REFERENCES

448

Chapter 29 Clinical Research in the Public Eye

450

INTRODUCTION

450

THE CULTURAL CONTEXT OF RESEARCH

451

SCIENCE AND POLITICS

455

PUBLIC–PRIVATE COLLABORATION

457

CONCLUSION

458

ACKNOWLEDGMENTS

459

REFERENCES

459

Part IX: Research in Special Populations

462

Chapter 30 Acute Illnesses, Critical Care, Emergency and Surgical Patients

464

INTRODUCTION

464

TRIAL DESIGN

464

USUAL CARE IN CRITICALLY ILL PATIENTS

467

INFORMED CONSENT

469

OUTCOMES

473

ADVERSE EVENTS

476

CONCLUSION

478

REFERENCES

478

Chapter 31 Psychiatric Disorders

482

INTRODUCTION

482

DIAGNOSTIC ISSUES

482

TYPES OF STUDIES

483

TOOLS

485

STATISTICAL AND DESIGN ISSUES

489

SPECIAL ISSUES

490

A PRACTICAL SCHEMATIC APPROACH

493

REFERENCES

495

Chapter 32 Geriatrics

498

INTRODUCTION

498

WHAT IS DIFFERENT ABOUT AGING RESEARCH?

498

HOW AN AGING PERSPECTIVE AFFECTS RESEARCH TOPICS AND APPROACHES

502

THE EFFECT OF AGING ON THE PRAGMATICS OF RESEARCH

507

CONCLUSIONS AND RECOMMENDATIONS

513

REFERENCES

513

Chapter 33 Pediatrics

518

INTRODUCTION

518

WHAT IS DIFFERENT ABOUT PEDIATRIC RESEARCH?

518

ORPHAN (RARE) DISEASES

520

PEDIATRIC CONDITIONS AS FOCUS OF INQUIRY

523

REGULATORY AND ETHICAL ENVIRONMENT FOR PEDIATRIC RESEARCH

524

CONCLUSION

525

REFERENCES

526

Part X: Population-Based Research

530

Chapter 34 Pharmacoeconomics: The Economic Evaluation of New Medical Technology

532

INTRODUCTION

532

THE EVALUATION OF NEW MEDICAL TECHNOLOGY: THE PRODUCER’S PERSPECTIVE

532

THE EVALUATION OF NEW MEDICAL TECHNOLOGY: THE END USER’S PERSPECTIVE

534

THE EVALUATION OF NEW MEDICAL TECHNOLOGY: SOCIETY’S PERSPECTIVE

536

COST–BENEFIT, COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS

538

CAN ONE EVER AVOID PUTTING MONETARY VALUES ON HEALTH BENEFITS?

543

UNRESOLVED CONTROVERSIES ON ECONOMIC VALUATIONS IN HEALTHCARE

545

NOTES

546

REFERENCES

546

Chapter 35 Introduction to Epidemiology

548

INTRODUCTION

548

DEFINITION AND ROLE OF EPIDEMIOLOGY

548

MEASURING OCCURRENCE OF DISEASE

550

MEASURING RISK AND ASSOCIATION

551

TYPES OF EPIDEMIOLOGICAL STUDIES

553

THREATS TO VALIDITY AND RELIABILITY

556

MOVING FROM ASSOCIATION TO CAUSATION

558

CLINICAL EPIDEMIOLOGY

560

SEX, GENDER, RACE AND ETHNICITY IN EPIDEMIOLOGY

560

SUMMARY

561

ACKNOWLEDGMENTS

561

RECOMMENDED RESOURCES

561

REFERENCES

561

Chapter 36 Health Services Research: Translating Discovery and Research into Practice and Policy

564

WHAT IS HEALTH SERVICES RESEARCH AND WHAT ARE ITS GOALS?

564

ASSESSING MEDICAL INTERVENTIONS: OUTCOMES, EFFECTIVENESS AND COST-EFFECTIVENESS

565

MEDICAL DECISION MAKING

568

QUALITY MEDICAL CARE

573

CONCLUSIONS

581

REFERENCES

582

Part XI: Prospectus

584

Chapter 37 The Future of Clinical Research

586

DEFINITION OF TRANSLATIONAL HUMAN RESEARCH

586

SUBGROUPING OF BIOLOGICAL SCIENTISTS

587

THE PATIENT-ORIENTED SCIENTIST AT THE BEGINNING OF THE TWENTY-FIRST CENTURY

589

THE TWENTY-FIRST CENTURY AND THE FUTURE

590

REFERENCES

591

Index

592

A

592

B

592

C

592

D

594

E

594

F

595

G

595

H

596

I

596

J

597

K

597

L

597

M

597

N

597

O

598

P

598

Q

599

R

599

S

599

T

600

U

600

V

600

W

600

X

600